CABA 241220 2.50C (CABA241220C2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CABA241220C2500

Watchlist

0.39
-0.06-13.33%

15min DelayTrading Nov 26 11:43 ET

0.60High0.35Low

Intraday

5D
Daily

News

Cabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024
RTTNewsNov 26 09:30 ET
Cabaletta Bio to Participate in Upcoming Investor Conferences in December
GlobeNewswireNov 26 08:00 ET
Cabaletta Bio Reports Q3 2024 Financial Results
TipRanksNov 18 22:54 ET
Express News | Cabaletta Bio Announces Presentation Of Updated CABA-201 Clinical Data At ACR Convergence 2024l; Says Safety Profile Suggested Favorable Risk-Benefit With No CRS Or ICANS In Majority Of Patients
BenzingaNov 18 07:22 ET
Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials
BenzingaNov 18 07:11 ET
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Moomoo NewsNov 18 04:33 ET · Ratings

Comments

Dps

Nov 19 14:57

$Cabaletta Bio (CABA.US)$ what happened to it

Dps

Oct 10 14:04

$Cabaletta Bio (CABA.US)$ poor stock … not growing at all

Dps

Oct 4 14:30

$Cabaletta Bio (CABA.US)$ what happened to it … no improvement at all

Jaguar8

Sep 25 15:39

NEWS

$Cabaletta Bio (CABA.US)$
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
Cabaletta Bio (Nasdaq: CABA) announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, featuring new and updated clinical data on CABA-201, their 4-1BB-containing fully human CD19-CAR T cell investigational therapy. The presentations will cover:
1. An oral presentation on the safety and efficacy of C...

frogoracletrading

Aug 19 09:00

$CABA Support / Resistance Levels

Testing the bottom of the GAP at 4.82. Here are the levels to keep on watch.
Larger Image: tradingview.com...
$Cabaletta Bio (CABA.US)$